Contact Us

Yes. AKT1 rescue experiments are gold-standard for cancer AKT research: • Construct design: use a codon-modified AKT1 sequence with a small C-terminal tag (FLAG, HA). Preserve PH domain (PIP3 binding), kinase domain (T308 activation site), and C-terminal hydrophobic motif (S473). • Kinase-dead rescue: K179M ATP-binding lysine mutation abolishes catalytic activity. • Cancer mutation rescue: ⭐ E17K PH domain activating mutation (HR+ breast cancer) — gold-standard for capivasertib pharmacology. • Constitutively active rescue: myr-AKT1 constitutive plasma membrane localization. • Functional readout: rescue should restore AKT1-specific cell survival/growth signaling. A-549-specific considerations: • A-549 is a human non-small cell lung carcinoma (NSCLC) cell line widely used for lung cancer drug development. • Lentiviral transduction is supported with moderate efficiency. • A-549's PI3K-AKT pathway activity makes it a relevant context for systematic AKT paralog research.

The choice depends on whether you are studying ANKH (progressive ankylosis protein homolog)'s role as a pyrophosphate transporter or modeling its functions in skeletal biology and emerging immune applications. The Knockout line is the standard tool for asking whether ANKH is required for these processes — ANKH is a transmembrane protein that mediates inorganic pyrophosphate (PPi) and citrate transport across the plasma membrane, with critical roles in skeletal mineralization (PPi inhibits hydroxyapatite formation); recent studies (Kirsch et al. 2021) have characterized ANKH-mediated ATP and citrate transport as an emerging mechanism in inflammation. Overexpression is useful for studying ANKH gain-of-function effects. For skeletal and emerging immune biology research, the EDITGENE ANKH Knockout in HCT 116 enables study of ANKH biology. ANKH gain-of-function mutations cause ⭐ craniometaphyseal dysplasia (autosomal dominant) and chondrocalcinosis (familial pseudogout) — these mutations increase ANKH activity. Rescue with wild-type or disease-mutant ANKH enables disease genotype-function studies. The knockout is valuable for studying pyrophosphate biology, skeletal mineralization, chondrocalcinosis disease modeling, and emerging ANKH-mediated immunometabolite transport.

Yes. ANKH rescue experiments require attention to membrane transporter architecture: • Construct design: use a codon-modified ANKH sequence with a small intracellular tag (FLAG, HA). ANKH has multiple transmembrane domains — preserve membrane topology. • CMD/chondrocalcinosis mutation rescue: gain-of-function mutations enable disease genotype-function studies (CMD mutations increase ANKH activity). • Surface localization validation: confirm plasma membrane ANKH localization before transport assays. • Functional readout: rescue should restore extracellular PPi efflux measured by enzymatic PPi assays. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on the experimental question. ACAP3 (ArfGAP with coiled-coil, ANK repeat and PH domain containing 3) is an Arf6 GTPase-activating protein with characterized roles in neuronal biology. The Knockout line is appropriate for asking whether ACAP3 is required for predicted activities — ACAP3 is an Arf6-specific GAP (GTPase-activating protein) with PH, ArfGAP, and ankyrin repeat domains; ACAP3 has been characterized in neuronal migration and neurite outgrowth through Arf6 regulation. Overexpression is useful for studying ACAP3 in heterologous expression contexts. For Arf6 signaling research, the EDITGENE ACAP3 Knockout in HeLa provides a clean genetic background for characterizing ACAP3-specific functions. Other ACAP family members (ACAP1, ACAP2) expression analysis aids interpretation. Rescue with wild-type or GAP-dead ACAP3 enables structure-function studies. The knockout is valuable for studying Arf6 GTPase regulation, membrane trafficking, and emerging ACAP3 functions in neuronal biology.

Yes. ACAP3 rescue experiments require attention to multi-domain architecture: • Construct design: use a codon-modified ACAP3 sequence with a small C-terminal tag (FLAG, HA). ACAP3 has BAR, PH, ArfGAP, and ankyrin repeat domains — preserve all elements. • GAP-dead rescue: ArfGAP domain arginine finger mutations abolish Arf6-GAP activity. • Functional readout: rescue should restore Arf6-GTP hydrolysis and membrane trafficking. HeLa transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying AAK1 (AP2-associated kinase 1)'s role in clathrin-mediated endocytosis or modeling its emerging functions as an antiviral and neuropathic pain target. The Knockout line is the standard tool for asking whether AAK1 is required for these processes — AAK1 is a Ser/Thr kinase that phosphorylates the μ2 subunit of the AP2 adaptor complex (T156), enhancing AP2-cargo interaction during clathrin-mediated endocytosis; AAK1 regulates receptor internalization and is hijacked by multiple viruses for entry. Overexpression is useful for studying AAK1 gain-of-function effects. For endocytosis and antiviral research, the EDITGENE AAK1 Knockout in A-549 is uniquely valuable — A-549 is a relevant epithelial/respiratory context for viral entry studies. Rescue with wild-type or kinase-dead AAK1 enables structure-function studies. The knockout is a critical specificity tool for ⭐ AAK1 inhibitors: ⭐ baricitinib (Olumiant, JAK inhibitor with AAK1 activity, repurposed for COVID-19 based in part on predicted AAK1-mediated antiviral effects on viral endocytosis), LP-935509, SGC-AAK1-1, and emerging AAK1-targeted approaches in neuropathic pain (AAK1 knockout mice show reduced pain) and antiviral therapy.

Yes. AAK1 rescue experiments are well-established for endocytosis research: • Construct design: use a codon-modified AAK1 sequence with a small C-terminal tag (FLAG, HA). AAK1 has N-terminal kinase domain and C-terminal clathrin/AP2-binding region — preserve all elements. • Kinase-dead rescue: K74A mutation in the ATP-binding lysine abolishes catalytic activity. • Functional readout: rescue should restore AP2 μ2 (T156) phosphorylation and clathrin-mediated endocytosis. A-549-specific considerations: • A-549 is a human non-small cell lung carcinoma (NSCLC) cell line widely used for lung cancer drug development. • Lentiviral transduction is supported with moderate efficiency. • A-549 is a versatile epithelial background for kinase and trafficking research.

The choice depends on the experimental question. AGO4 (argonaute 4) is one of four Argonaute family proteins (AGO1-4) that load small RNAs to mediate gene silencing. The Knockout line is appropriate for asking whether AGO4 is required for predicted activities — AGO4 is one of four mammalian Argonaute proteins; AGO2 is the principal 'slicer' (endonuclease activity for siRNA-mediated cleavage), while AGO1, AGO3, and AGO4 lack robust slicer activity but participate in miRNA-mediated translation repression. Overexpression is useful for studying AGO4 in heterologous expression contexts. Important consideration: AGO1, AGO2, AGO3 paralog expression analysis aids interpretation given substantial functional overlap — single AGO4 knockout may show modest phenotypes if other AGOs compensate. For colorectal cancer-context Argonaute research, the EDITGENE AGO4 Knockout in HCT 116 enables study of AGO4-specific functions in MSI-H/dMMR colorectal cancer context. Rescue with wild-type AGO4 is the standard specificity control. The knockout is valuable for studying Argonaute family biology, miRNA-mediated regulation, and emerging AGO4-specific functions in cancer biology.

Yes. AGO4 rescue experiments require attention to Argonaute architecture: • Construct design: use a codon-modified AGO4 sequence with a small C-terminal tag (FLAG, HA). AGO4 has N, PAZ, MID, and PIWI domains (canonical Argonaute architecture but lacking robust slicer activity) — preserve all elements. • small RNA-binding-deficient rescue: PAZ/MID domain mutations disrupt small RNA loading. • Functional readout: rescue should restore AGO4-dependent miRNA target repression. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

AKT (Protein Kinase B) is a family of three paralogous serine/threonine kinases (AKT1/PKBα, AKT2/PKBβ, AKT3/PKBγ) that are activated downstream of PI3K signaling — PI3K generates PIP3, which recruits AKT to the plasma membrane via its PH domain; AKT is then phosphorylated at T308 (activation loop, by PDK1) and S473 (hydrophobic motif, by mTORC2) for full activation. AKT family members share substantial substrate scope but have distinct tissue expression and functions: AKT1 is broadly expressed and important in cell survival/growth; AKT2 is enriched in insulin-sensitive tissues (liver, muscle, adipose) and central to insulin signaling; AKT3 is enriched in brain and testis with roles in neural development. Substantial paralog redundancy means that single-isoform knockouts often show modest phenotypes — paired and combination knockouts are essential for systematic functional dissection. This AKT2 Knockout in A-549 enables study of AKT2-specific functions — AKT2 is enriched in insulin-sensitive tissues (liver, muscle, adipose) and is central to insulin-mediated glucose uptake (GLUT4 translocation); AKT2 loss-of-function causes severe insulin resistance and diabetes mellitus in mice and rare human cases. Overexpression is useful for studying AKT2 gain-of-function effects. Important consideration: AKT1/AKT3 paralog expression analysis aids interpretation given substantial redundancy. This product is part of EDITGENE's complete AKT paralog dissection toolkit in A-549 (single AKT1, single AKT2, double AKT1&AKT2, double AKT1&AKT3, double AKT2&AKT3). Rescue with wild-type, kinase-dead (K181M), or constitutively active (myristoylated) AKT2 enables structure-function studies. The knockout is valuable for studying AKT2-specific insulin signaling and AKT inhibitor isoform selectivity.

Yes. AKT2 rescue experiments are well-established for insulin signaling research: • Construct design: use a codon-modified AKT2 sequence with a small C-terminal tag (FLAG, HA). Preserve PH domain (PIP3 binding), kinase domain (T309 activation site), and C-terminal hydrophobic motif (S474). • Kinase-dead rescue: K181M ATP-binding lysine mutation abolishes catalytic activity. • Constitutively active rescue: myr-AKT2 constitutive plasma membrane localization. • Patient mutation rescue: rare AKT2 loss-of-function mutations in human insulin resistance can be modeled. • Functional readout: rescue should restore AKT2-specific insulin-induced GLUT4 translocation. A-549-specific considerations: • A-549 is a human non-small cell lung carcinoma (NSCLC) cell line widely used for lung cancer drug development. • Lentiviral transduction is supported with moderate efficiency. • A-549's PI3K-AKT pathway activity makes it a relevant context for systematic AKT paralog research.

The choice depends on whether you are studying ADRB2 (β2-adrenergic receptor, β2-AR)'s role as a prototypical Gs-coupled GPCR or modeling its functions in asthma pharmacology and emerging biased agonism research. The Knockout line is the standard tool for asking whether β2-AR is required for these processes — ADRB2 is a Gs-coupled seven-transmembrane GPCR activated by epinephrine and norepinephrine; β2-AR is highly expressed in bronchial smooth muscle (target of asthma bronchodilators), cardiac myocytes, vascular smooth muscle, immune cells, and many other tissues; β2-AR is one of the most studied GPCRs and a foundational model for GPCR structural biology (Kobilka 2012 Nobel Prize). Overexpression is useful for studying β2-AR gain-of-function effects. For asthma pharmacology and GPCR research, the EDITGENE ADRB2 Knockout in HeLa is uniquely valuable — HeLa supports systematic structure-function studies of this prototypical GPCR. Rescue with wild-type, signaling-deficient (DRY motif mutations), or β-arrestin-binding-deficient β2-AR enables comprehensive biased agonism research. The knockout is a critical specificity tool for ⭐⭐ short-acting β2-AR agonists (SABAs: ⭐ albuterol/salbutamol, levalbuterol), long-acting β2-AR agonists (LABAs: ⭐ salmeterol, formoterol, indacaterol, olodaterol, vilanterol), inverse agonists (carvedilol, propranolol), and emerging biased β2-AR ligands.

Yes. β2-AR rescue experiments are gold-standard for GPCR research: • Construct design: use a codon-modified ADRB2 sequence with a small intracellular C-terminal tag (FLAG, HA) — note that C-terminal tags may affect β-arrestin recruitment; consider alternative tag placement for biased agonism research. • Surface localization validation: confirm plasma membrane β2-AR by cell surface staining before ligand binding studies. • Signaling-deficient rescue: DRY motif mutations (D131N, R132H, Y133A) disrupt Gs-coupling. • Phosphorylation-site mutant rescue: C-terminal Ser/Thr cluster mutations affect GRK-mediated phosphorylation and β-arrestin recruitment. • Constitutively active rescue: CAM (constitutively active mutation) variants for studying activated receptor states. • Functional readout: rescue should restore isoproterenol-induced cAMP elevation and β-arrestin recruitment. HeLa transduces efficiently with lentivirus and supports stable rescue line generation for systematic biased agonism research.

The choice depends on whether you are studying APOD in lung cancer context. The Knockout line is the standard tool for asking whether APOD is required for predicted activities in NSCLC context — APOD has been characterized in various cancer contexts with reported pro-survival functions. Overexpression is useful for studying APOD gain-of-function effects. For lung cancer research, the EDITGENE APOD Knockout in A-549 is relevant. This product complements the parallel APOD Knockout in HEK293T (also available) for cross-background validation. Rescue with wild-type APOD is the standard specificity control. The knockout is valuable for studying APOD biology in cancer and emerging context-dependent APOD functions.

Yes. APOD rescue in A-549 follows the same considerations as APOD/HEK293T: • Construct design: same considerations as APOD/HEK293T rescue. • Cross-background validation: parallel rescue in A-549 (lung cancer) and HEK293T provides cross-tissue validation. • Functional readout: rescue should restore APOD-dependent phenotypes. A-549 transduces efficiently with lentivirus and supports stable rescue line generation.